drugset / Trial / NCT01151761
Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine progression-free survival at 12 months for stereotactic body radiotherapy (SBRT) and chemotherapy for unresectable hilar cholangiocarcinoma (CCA).
Timeline
- Start
- 2011-01
- Primary completion
- 2012-04
- Completion
- 2012-07
Outcome
Outcome not reported
Stopped (Enrollment): “Poor accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Carboplatin | Small molecule | 2 unknown | Intravenous |
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 100 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 200 mg/m2 | — |